Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease - A population-based case-control study

被引:533
作者
Juul, A
Scheike, T
Davidsen, M
Gyllenborg, J
Jorgensen, T
机构
[1] Rigshosp, Sect 5064, Dept Growth & Reprod, DK-2100 Copenhagen 0, Denmark
[2] Panum Inst, Dept Biostat, Copenhagen, Denmark
[3] Univ Copenhagen, Ctr Prevent Med, Med Dept M, Copenhagen, Denmark
[4] Univ Copenhagen, Glostrup Cty Hosp, Copenhagen, Denmark
关键词
atherosclerosis; epidemiology; myocardial infarction; growth substances;
D O I
10.1161/01.CIR.0000027563.44593.CC
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Insulin-like growth factor I (IGF-I) has been suggested to be involved in the pathogenesis of atherosclerosis. We hypothesize that low IGF-I and high IGFBP-3 levels might be associated with increased risk of ischemic heart disease (IHD). Methods and Results-We conducted a nested case-control study within a large prospective study on cardiovascular epidemiology (DAN-MONICA). We measured IGF-I and IGFBP-3 in serum from 231 individuals who had a diagnosis of IHD 7.63 years after blood sampling and among 374 control subjects matched for age, sex, and calendar time. At baseline when all individuals were free of disease, subjects in the low IGF-I quartile had significantly higher risk of IHD during the 15-year follow-up period, with a relative risk (RR) of 1.94 (95% CI, 1.03 to 3.66) of IHD compared with the high IGF-I quartile group, when IGFBP-3, body mass index, smoking, menopause, diabetes, and use of antihypertensives were controlled for. Conversely, individuals in the high IGFBP-3 quartile group had an adjusted RR of 2.16 (95% CI, 1.18 to 3.95) of having IHD. Identification of a high-risk population with low IGF-I and high IGFBP-3 levels resulted in markedly higher risk of IHD (RR 4.07; 95% CI, 1.48 to 11.22) compared with the index group. Conclusions-Individuals without IHD but with low circulating IGF-I levels and high IGFBP-3 levels have significantly increased risk of developing IHD during a 15-year follow-up period. Our findings suggest that IGF-I may be involved in the pathogenesis of IHD.
引用
收藏
页码:939 / 944
页数:6
相关论文
共 27 条
[1]   COMPARISON OF ACID ETHANOL EXTRACTION AND ACID GEL-FILTRATION PRIOR TO IGF-I AND IGF-II RADIOIMMUNOASSAYS - IMPROVEMENT OF DETERMINATIONS IN ACID ETHANOL EXTRACTS BY THE USE OF TRUNCATED IGF-I AS RADIOLIGAND [J].
BANG, P ;
ERIKSSON, U ;
SARA, V ;
WIVALL, IL ;
HALL, K .
ACTA ENDOCRINOLOGICA, 1991, 124 (06) :620-629
[2]   A SPECIFIC RADIOIMMUNOASSAY FOR THE GROWTH-HORMONE (GH)-DEPENDENT SOMATOMEDIN-BINDING PROTEIN - ITS USE FOR DIAGNOSIS OF GH DEFICIENCY [J].
BLUM, WF ;
RANKE, MB ;
KIETZMANN, K ;
GAUGGEL, E ;
ZEISEL, HJ ;
BIERICH, JR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (05) :1292-1298
[3]   Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X [J].
Botker, HE ;
Skjaerbaek, C ;
Eriksen, UH ;
Schmitz, O ;
Orskov, H .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (07) :961-&
[4]   Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors [J].
Bülow, B ;
Hagmar, L ;
Eskilsson, J ;
Erfurth, EM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :574-584
[5]   The insulin-like growth factor axis and plasma lipid levels in the elderly [J].
Ceda, GP ;
Dall'aglio, E ;
Magnacavallo, A ;
Vargas, N ;
Fontana, V ;
Maggio, M ;
Valenti, G ;
Lee, PDK ;
Hintz, RL ;
Hoffman, AR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) :499-502
[6]   Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries [J].
Conti, E ;
Andreotti, F ;
Sestito, A ;
Riccardi, P ;
Menini, E ;
Crea, F ;
Maseri, A ;
Lanza, GA .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (08) :973-+
[7]  
DIEZ J, 1993, J HUM HYPERTENS, V7, P479
[8]  
FERNS GAA, 1991, ARTERY, V18, P197
[9]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[10]  
Frystyk J, 1999, DIABETES-METAB RES, V15, P314, DOI 10.1002/(SICI)1520-7560(199909/10)15:5<314::AID-DMRR56>3.3.CO